Gurgaon, Oct.29 (ANI): The Board of Directors of Ranbaxy Laboratories Limited, at its meeting held today, announced consolidated sales of Rs.27.5 billion for Quarter three, which was a marginal improvement on the same period in fiscal 2012-13 (Rs.26.7 billion).
A release by the company said that sales had been impacted by the new pricing policy and trade concerns in India and the absence of any post exclusivity sales during the quarter
It also said that earnings before interest, tax, depreciation and Amortization (EBITDA) was Rs.2 billion.
The company release also said that financial performance for YTD ending September 30, 2013 was Rs.77.5 billion, while EBITDA was Rs.5.5 billion.
Ranbaxy said the following exceptional items impacted profit:
.The depreciation of the INR against the USD, though favourable to Ranbaxy's export business had an adverse impact on the Company mainly on account of application of the accounting standards that require marking to market the entire derivatives and foreign currency denominated loans outstanding.
Gurgaon, Oct.29 (ANI): The Board of Directors of Ranbaxy Laboratories Limited, at its meeting held today, announced consolidated sales of Rs.27.5 billion for Quarter three, which was a marginal improvement on the same period in fiscal 2012-13 (Rs.26.7 billion).
A release by the company said that sales had been impacted by the new pricing policy and trade concerns in India and the absence of any post exclusivity sales during the quarter
It also said that earnings before interest, tax, depreciation and Amortization (EBITDA) was Rs.2 billion.
The company release also said that financial performance for YTD ending September 30, 2013 was Rs.77.5 billion, while EBITDA was Rs.5.5 billion.
Ranbaxy said the following exceptional items impacted profit:
.The depreciation of the INR against the USD, though favourable to Ranbaxy's export business had an adverse impact on the Company mainly on account of application of the accounting standards that require marking to market the entire derivatives and foreign currency denominated loans outstanding.